Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419203 | 0.87 | MAPK1 (0.76) | MAPK1ALOX15RAB9ANPC1KCNMA1 | |
| Bromide SCHEMBL27908055 | 0.86 | MAPK1 (0.74) | MAPK1ALOX15RAB9ANPC1KCNMA1 | |
| SCHEMBL4286353 | 0.79 | ADORA2A (0.73) | MAPK1ALOX15RAB9ANPC1KCNMA1 | |
| SCHEMBL7692575 | 0.76 | MEN1 (0.62) | MAPK1ALOX15RAB9ANPC1ADRB2 | |
| SCHEMBL16078340 | 0.76 | RAB9A (0.64) | MAPK1ALOX15RAB9ANPC1KCNMA1 | |
| SCHEMBL2381187 | 0.76 | GAA (0.53) | MAPK1ALOX15RAB9ANPC1KCNMA1 | |
| SCHEMBL714175 | 0.75 | MAPK1 (0.73) | MAPK1ALOX15RAB9ANPC1ADRB2 | |
| SCHEMBL16363830 | 0.75 | MAPK1 (1.00) | MAPK1ALOX15RAB9ANPC1MAPT | |
| SCHEMBL2378260 | 0.75 | GAA (0.55) | MAPK1ALOX15RAB9ANPC1ADRB2 | |
| SCHEMBL24934051 | 0.74 | RAB9A (0.72) | MAPK1ALOX15RAB9ANPC1KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-09 | — | — | US | disclosed |
| US-9475782-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | disclosed |
| EP-1716127-B1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT LABORATORIES (US) | 2013-12-05 | — | — | US | disclosed |
| US-8481576-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8431604-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| EP-2380885-A1 | Guanidine compounds and use of same as binding partners for 5-HT5 receptors | Abbott GmbH & Co. KG (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-09-29 | — | — | US | disclosed |
| EP-2366697-A1 | Guanidine compounds and use of same as binding partners for 5-HT5 receptors | Abbott GmbH & Co. KG (DE) | 2011-09-21 | — | — | EP | disclosed |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | MAPK1 1791/4885ALOX15 1109/4885RAB9A 1420/4885 |
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, GRK5 | MAPK1 1732/4885ALOX15 1365/4885RAB9A 1428/4885 |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | HTR5A, GRM5, TAAR5 | MAPK1 1791/4885ALOX15 1109/4885RAB9A 1420/4885 |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | MAPK1 1791/4885ALOX15 1109/4885RAB9A 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.